- Home
- RENB vs NOTV Comparison
RENB vs NOTV Comparison
Compare RENB & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- NOTV
- Stock Information
- Founded
- RENB 2011
- NOTV 1974
- Country
- RENB United States
- NOTV United States
- Employees
- RENB N/A
- NOTV N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- RENB Health Care
- NOTV Health Care
- Exchange
- RENB Nasdaq
- NOTV Nasdaq
- Market Cap
- RENB 62.0M
- NOTV 69.4M
- IPO Year
- RENB N/A
- NOTV 1997
- Fundamental
- Price
- RENB $0.28
- NOTV $2.03
- Analyst Decision
- RENB
- NOTV Strong Buy
- Analyst Count
- RENB 0
- NOTV 1
- Target Price
- RENB N/A
- NOTV $5.00
- AVG Volume (30 Days)
- RENB 8.2M
- NOTV 770.3K
- Earning Date
- RENB 05-15-2025
- NOTV 08-07-2025
- Dividend Yield
- RENB N/A
- NOTV N/A
- EPS Growth
- RENB N/A
- NOTV N/A
- EPS
- RENB N/A
- NOTV N/A
- Revenue
- RENB N/A
- NOTV $480,402,000.00
- Revenue This Year
- RENB N/A
- NOTV $4.99
- Revenue Next Year
- RENB N/A
- NOTV $5.39
- P/E Ratio
- RENB N/A
- NOTV N/A
- Revenue Growth
- RENB N/A
- NOTV N/A
- 52 Week Low
- RENB $0.27
- NOTV $1.15
- 52 Week High
- RENB $2.10
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- RENB 38.32
- NOTV 46.28
- Support Level
- RENB $0.33
- NOTV $1.66
- Resistance Level
- RENB $0.37
- NOTV $3.19
- Average True Range (ATR)
- RENB 0.04
- NOTV 0.20
- MACD
- RENB -0.01
- NOTV -0.04
- Stochastic Oscillator
- RENB 6.24
- NOTV 40.11
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.